Related Experiment Video
Updated: Feb 21, 2026
Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
Published on: April 11, 2018
Recent progress in translational cystic fibrosis research using precision medicine strategies
Deborah M Cholon1, Martina Gentzsch2
1Marsico Lung Institute/Cystic Fibrosis Research Center, University of North Carolina, Chapel Hill, NC, USA.
Abstract:
Significant progress has been achieved in developing precision therapies for cystic fibrosis; however, highly effective treatments that target the ion channel, CFTR, are not yet available for many patients. As numerous CFTR therapeutics are currently in the clinical pipeline, reliable screening tools capable of predicting drug efficacy to support individualized treatment plans and translational research are essential. The utilization of bronchial, nasal, and rectal tissues from individual cystic fibrosis patients for drug testing using in vitro assays such as electrophysiological measurements of CFTR activity and evaluation of fluid movement in spheroid cultures, has advanced the prediction of patient-specific responses. However, for precise prediction of drug effects, in vitro models of CFTR rescue should incorporate the inflamed cystic fibrosis airway environment and mimic the complex tissue structures of airway epithelia. Furthermore, novel assays that monitor other aspects of successful CFTR rescue such as restoration of mucus characteristics, which is important for predicting mucociliary clearance, will allow for better prognoses of successful therapies in vivo. Additional cystic fibrosis treatment strategies are being intensively explored, such as development of drugs that target other ion channels, and novel technologies including pluripotent stem cells, gene therapy, and gene editing. The multiple therapeutic approaches available to treat the basic defect in cystic fibrosis combined with relevant precision medicine models provide a framework for identifying optimal and sustained treatments that will benefit all cystic fibrosis patients.
Insights
Developing better cystic fibrosis (CF) treatments requires advanced screening tools. These tools predict drug efficacy using patient tissues and advanced models to improve personalized medicine for CFTR modulators.
Area of Science:
- Biomedical research
- Translational medicine
- Pharmacology
Background:
- Precision therapies for cystic fibrosis (CF) are advancing, but effective treatments targeting the cystic fibrosis transmembrane conductance regulator (CFTR) protein are still needed for many patients.
- The development of numerous CFTR therapeutics in clinical trials necessitates reliable screening tools for predicting drug efficacy.
- Current in vitro assays using patient tissues (bronchial, nasal, rectal) aid in predicting patient-specific responses to CFTR modulators.
Purpose of the Study:
- To highlight the need for improved in vitro models for predicting CFTR therapeutic efficacy.
- To emphasize the importance of incorporating airway inflammation and complex tissue structures into CF models.
- To underscore the value of novel assays assessing mucus characteristics and mucociliary clearance for predicting treatment success.
Main Methods:
- Utilizing patient-derived tissues (bronchial, nasal, rectal) for in vitro drug testing.
- Employing electrophysiological measurements of CFTR activity and fluid movement in spheroid cultures.
- Developing novel assays to evaluate mucus characteristics and mucociliary clearance.
Main Results:
- In vitro assays using patient tissues show promise in predicting patient-specific responses to CFTR modulators.
- Incorporating inflamed airway environments and complex tissue structures is crucial for precise drug effect prediction.
- Monitoring mucus characteristics alongside CFTR activity provides a more comprehensive assessment of therapeutic potential.
Conclusions:
- Advanced in vitro models that mimic the CF airway environment are essential for precise prediction of CFTR therapeutic efficacy.
- Novel assays assessing mucus properties will enhance the prediction of successful mucociliary clearance in vivo.
- Integrating diverse therapeutic strategies with precision medicine models offers a pathway to optimal, sustained treatments for all CF patients.
Related Concept Videos
01:24Cystic Fibrosis: Management
Sinus disease and chronic...
01:29Pharmacogenomics: Identification of New Drug Targets
01:23Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
01:29Microorganisms in Medicine and Therapeutics
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase